Oxford Drug Design

Oxford, United Kingdom · Founded 2001 · Privately Held (backing)

Developer of an artificial intelligence-driven drug discovery platform designed to support the identification and development of new therapeutic candidates. Oxford Drug Design is based in Oxford, United Kingdom and was founded in 2001. Its last reported valuation was $12.7 million in Dec 2025. It has raised $16.5 million.

Last reported valuation
$12.7M
Oct 2026
Priced at
—
Total raised
$16.5M
Last round
—

Who backs Oxford Drug Design?

22 investors
InvestorType
Innovate UKOther
European CommissionOther
SyndicateRoomVenture capital
University of Oxford—
Cambridge AngelsAngel
Meltwind Advisory—
ACF InvestorsVenture capital
CARB-XOther
Ronjon NagOther
University of Oxford EndowmentOther
+ 12 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Oxford Drug Design investors

22 investors are on record for Oxford Drug Design, including Innovate UK, European Commission, SyndicateRoom and University of Oxford.

Free account
More of Oxford Drug Design with a free account
  • ·The complete investor list: 22 names
  • ·Watch Oxford Drug Design: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 22 firms already write checks for companies like Oxford Drug Design. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View